Wednesday, July 16, 2008 - 18:30

Innate Pharma SA announces today that IPH 1101 in combination with rituximab was authorized to enter the second part of the Phase I/II trial in follicular non-Hodgkin's lymphoma.

AttachmentSize
PR in english99.65 KB
CP en français79.24 KB